Payment overview · 2025
General Payments
$109.18
6 reported records · 4 companies
Healthcare provider profile · identity verified
Mohammed Samiuddin, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · AMARILLO, TX · NPI 1215152442
Verified facts
What the public records show
CMS Open Payments records show Mohammed Samiuddin, M.D. received $109.18 in general payments during 2025 across 6 reported records.
Sumitomo Pharma America, Inc. accounted for 50.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Synthroid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.44 | 50.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.30 | 20.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.77 | 14.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.67 | 14.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $109.18 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.44 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 66 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
149 | 40 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
66 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 827 | 231 |
| Atorvastatin Calcium | Atorvastatin Calcium | 775 | 212 |
| Losartan Potassium | Losartan Potassium | 604 | 182 |
| Amlodipine Besylate | Amlodipine Besylate | 481 | 140 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 453 | 142 |
| Gabapentin | Gabapentin | 448 | 133 |
| Omeprazole | Omeprazole | 389 | 128 |
| Trazodone Hcl | Trazodone Hcl | 361 | 115 |
| Memantine Hcl | Memantine Hcl | 360 | 113 |
| Simvastatin | Simvastatin | 347 | 97 |
| Metformin Hcl | Metformin Hcl | 336 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 317 | 91 |
| Montelukast Sodium | Montelukast Sodium | 299 | 76 |
| Lisinopril | Lisinopril | 279 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 270 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 75 |
| Donepezil Hcl | Donepezil Hcl | 257 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 248 | 69 |
| Sertraline Hcl | Sertraline Hcl | 244 | 73 |
| Tramadol Hcl | Tramadol Hcl | 237 | 51 |
| Finasteride | Finasteride | 233 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 209 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 194 | 59 |
| Alprazolam | Alprazolam | 172 | 43 |
| Eliquis | Apixaban | 155 | 41 |
| Furosemide | Furosemide | 150 | 57 |
| Carvedilol | Carvedilol | 149 | 53 |
| Synthroid | Levothyroxine Sodium | 149 | 40 |
| Prednisone | Prednisone | 144 | 96 |
| Allopurinol | Allopurinol | 143 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 54 |
| Glipizide Er | Glipizide | 136 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 47 |
| Ezetimibe | Ezetimibe | 134 | 42 |
| Spironolactone | Spironolactone | 131 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 36 |
| Lactulose | Lactulose | 113 | 38 |
| Metformin Hcl Er | Metformin Hcl | 113 | 42 |
| Potassium Chloride | Potassium Chloride | 108 | 35 |
| Mirtazapine | Mirtazapine | 104 | 32 |
| Buspirone Hcl | Buspirone Hcl | 99 | 27 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 94 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 45 |
| Glimepiride | Glimepiride | 92 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 25 |
| Celecoxib | Celecoxib | 84 | 39 |
| Clonazepam | Clonazepam | 84 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 81 | 68 |
| Bupropion Xl | Bupropion Hcl | 75 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 18 |
| Methocarbamol | Methocarbamol | 74 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 19 |
| Lorazepam | Lorazepam | 73 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 71 | 34 |
| Alendronate Sodium | Alendronate Sodium | 69 | 21 |
| Azithromycin | Azithromycin | 69 | 64 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 20 |
| Meloxicam | Meloxicam | 68 | 24 |
| Nifedipine Er | Nifedipine | 68 | 20 |
| Gemtesa | Vibegron | 66 | 22 |
| Januvia | Sitagliptin Phosphate | 66 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 65 | 14 |
| Amoxicillin | Amoxicillin | 64 | 50 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 54 |
| Atenolol | Atenolol | 63 | 18 |
| Cephalexin | Cephalexin | 63 | 55 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 63 | 53 |
| Ibandronate Sodium | Ibandronate Sodium | 63 | 23 |
| Estradiol | Estradiol | 62 | 25 |
| Famotidine | Famotidine | 62 | 25 |
| Temazepam | Temazepam | 62 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | 21 |
| Ozempic | Semaglutide | 59 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 16 |
| Valsartan | Valsartan | 56 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 17 |
| Cefdinir | Cefdinir | 55 | 52 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 14 |
| Glipizide | Glipizide | 49 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 14 |
| Mupirocin | Mupirocin | 48 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 28 |
| Nystatin | Nystatin | 46 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 40 |
| Jardiance | Empagliflozin | 44 | 11 |
| Irbesartan | Irbesartan | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Diazepam | Diazepam | 41 | 12 |
| Metronidazole | Metronidazole | 41 | 35 |
| Meclizine Hcl | Meclizine Hcl | 40 | 22 |
| Paxlovid | Nirmatrelvir/Ritonavir | 40 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 11 |
| Valacyclovir | Valacyclovir Hcl | 40 | 19 |
| Myrbetriq | Mirabegron | 38 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 32 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Trospium Chloride | Trospium Chloride | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 12 |
| Nitroglycerin | Nitroglycerin | 26 | 17 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | 12 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | 12 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Mesalamine | Mesalamine | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 16 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Mexiletine Hcl | Mexiletine Hcl | 13 | suppressed |
| Probenecid | Probenecid | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Estazolam | Estazolam | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109.18 · 6 records | Sumitomo Pharma America, Inc. | GEMTESA, LINZESS, REXULTI, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error